ScoreWhy is Sprint Bioscience AB ?
1
With a growth in Operating Profit of 134.9%, the company declared Very Positive results in Mar 26
- The company has declared positive results for the last 2 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at SEK 69.76 MM
- NET SALES(HY) Higher at SEK 133.91 MM
- NET PROFIT(HY) Higher at SEK 100.28 MM
2
With ROE of 76.97%, it has a very attractive valuation with a 1.89 Price to Book Value
- Over the past year, while the stock has generated a return of 801.61%, its profits have risen by 601.9% ; the PEG ratio of the company is 0
3
Market Beating performance in long term as well as near term
- Along with generating 801.61% returns in the last 1 year, the stock has outperformed OMX Stockholm 30 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Sprint Bioscience AB should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Sprint Bioscience AB for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Sprint Bioscience AB
801.61%
1.63
138.52%
OMX Stockholm 30
30.13%
1.89
15.95%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
58.16%
EBIT Growth (5y)
34.70%
EBIT to Interest (avg)
-23.27
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-5.17
Sales to Capital Employed (avg)
5.26
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
7.10%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
2
Industry P/E
Price to Book Value
1.89
EV to EBIT
1.01
EV to EBITDA
1.00
EV to Capital Employed
-13.03
EV to Sales
0.59
PEG Ratio
0.01
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
76.97%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend29What is working for the Company
OPERATING CASH FLOW(Y)
Highest at SEK 69.76 MM
NET SALES(HY)
Higher at SEK 133.91 MM
NET PROFIT(HY)
Higher at SEK 100.28 MM
ROCE(HY)
Highest at 153.73%
RAW MATERIAL COST(Y)
Fallen by -97.1% (YoY
CASH AND EQV(HY)
Highest at SEK 235.03 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 17.39 times
-11What is not working for the Company
DEBT-EQUITY RATIO
(HY)
Highest at -101.92 %
OPERATING PROFIT(Q)
Lowest at SEK -14.07 MM
PRE-TAX PROFIT(Q)
Lowest at SEK -12.89 MM
NET PROFIT(Q)
Lowest at SEK -12.89 MM
EPS(Q)
Lowest at SEK -0.12
Here's what is working for Sprint Bioscience AB
Net Sales
At SEK 133.91 MM has Grown at 340.84%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (SEK MM)
Net Sales
Higher at SEK 133.91 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (SEK MM)
Operating Cash Flow
Highest at SEK 69.76 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (SEK MM)
Cash and Eqv
Highest at SEK 235.03 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debtors Turnover Ratio
Highest at 17.39 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -97.1% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Sprint Bioscience AB
Pre-Tax Profit
At SEK -12.89 MM has Fallen at -128.52%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (SEK MM)
Net Profit
At SEK -12.89 MM has Fallen at -128.52%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (SEK MM)
Operating Profit
Lowest at SEK -14.07 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (SEK MM)
Pre-Tax Profit
Lowest at SEK -12.89 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (SEK MM)
Net Profit
Lowest at SEK -12.89 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (SEK MM)
EPS
Lowest at SEK -0.12
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (SEK)
Debt-Equity Ratio
Highest at -101.92 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
